TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14715864
Drug: Repaglinide (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (8 mg)
Study: 8214179
Drug: Group psychotherapy
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychotherapy (90-minute weekly sessions for 10 weeks)
Study: 3304367
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate 40 mg twice a day
Study: 30003027
Drug: S-Ketamine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Ketamine (initial bolus 1 mg/kg and continuous infusion of 0.015625 mg/kg/min with dosage reduction -10%/10 min)
Study: 27043952
Drug: Trauma-Focused Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-Focused Cognitive Behavioral Therapy (Tf-CBT)
Study: 24878085
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + metformin (850 mg three times a day)
Study: 24878085
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + metformin
Study: 18047502
Drug: DVPX 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVPX 250 mg
Study: 12829154
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus amifostine (340 mg/m2 i.v., 15 min before RT)
Study: 7438385
Drug: Naloxone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.2 mg/kg over 1 minute
Study: 29891906
Drug: Natural hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural hirudin and subcutaneous LMWH-calcium (test group)
Study: 29891906
Drug: Subcutaneous LMWH-calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous LMWH-calcium (control group)
Study: 25473882
Drug: GSK1265744 (744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 200 mg subcutaneously
Study: 25473882
Drug: GSK1265744 (744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 200 mg IM
Study: 25473882
Drug: GSK1265744 (744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 400 mg IM
Study: 25473882
Drug: GSK1265744 (744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 (744) LA 800 mg IM followed by a second injection of 800 mg IM after 12 weeks
Study: 25473882
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) LA 1200 mg IM at month 3 and 900 or 600 mg IM at month 4
Study: 6763435
Drug: Oral prednisone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisone, 10 mg thrice daily, continued until clinical remission, maximally 12 weeks.
Study: 29436064
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of amitriptyline at bedtime for 2 months
Study: 27161894
Drug: Cholecalciferol (50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (50,000 IU twice weekly)
Study: 27161894
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 drops of a placebo solution twice weekly)
Study: 26466328
Drug: Salbutamol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (400 μg)
Study: 22457014
Drug: Ipratropium (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium (80 μg)
Study: 16042675
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg) and Itraconazole (100 mg, first dose 200 mg)
Study: 12353302
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg daily warfarin
Study: 12353302
Drug: Variable dose
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable dose warfarin (PT 1.3‐1.5 times the normal PT)
Study: 10419991
Drug: Prenatal supplements
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal supplements containing iron + folate + zinc (15 mg zinc)
Study: 10419991
Drug: Prenatal supplements
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal supplements containing iron + folate (without zinc)
Study: 7480534
Drug: Capsule associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule associated with high frequency of reinforcement (greater monetary payoff)
Study: 7480534
Drug: Capsule associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule associated with low frequency of reinforcement (lower monetary payoff)
Study: 7480534
Drug: Self-administration results
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration results
Study: 2124648
Drug: Piperazine oestrone
Normalized name: Piperazine
DrugBank: Piperazine (DB00592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperazine oestrone sulphate (PE1S, 2.5 mg/day)
Study: 2124648
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (E2V, 2.0 mg/day)
Study: 2124648
Drug: PE1S in
Normalized name: Immunoglobulin g 1 (human monoclonal pe1-1 anti-hepatitis b virus surface antigen), disulfide with human monoclonal pe1-1 .lambda.-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE1S in combination with levonorgestrel (LNG, 250 micrograms/day)
Study: 6770707
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium cromoglycate (200 mg four times daily for 4 weeks)
Study: 30039199
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg oral dose
Study: 28616765
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g kg‐1 RSM
Study: 28616765
Drug: 450 g
Normalized name: IODINE 450 g in 10 L TOPICAL LIQUID [UDDERBLEND]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 g kg‐1 RSM
Study: 28616765
Drug: 600 g
Normalized name: PETROLATUM 600 g in 1000 g TOPICAL OINTMENT [EltaMD Laser Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 g kg‐1 RSM
Study: 28616765
Drug: 450 g
Normalized name: IODINE 450 g in 10 L TOPICAL LIQUID [UDDERBLEND]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 g kg‐1 RSM and 600 g kg‐1 RSM
Study: 26222270
Drug: Treatment aiming
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment aiming at normoglycemia (n = 33)
Study: 23537332
Drug: Telemonitoring intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemonitoring intervention (daily self-measurements of respiratory-rate, heart-rate, blood pressure, oxygen saturation, weight, body temperature, and health status questionnaire)
Study: 16860830
Drug: DEC alone
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC alone (6 mg/kg)
Study: 16860830
Drug: DEC and
Normalized name: insulin degludec and liraglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC and albendazole (400 mg)
Study: 16860830
Drug: DEC alone
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC alone (6 mg/kg) and DEC and albendazole (400 mg)
Study: 8311536
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol-valerate
Study: 3013044
Drug: Fentanyl (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.005 mg/kg b.w.)
Study: 3013044
Drug: Buprenorphine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.01 mg/kg b.w.)
Study: 3013044
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fentanyl and buprenorphine
Study: 29912266
Drug: Monthly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly active asking
Study: 29912266
Drug: Daily self-report
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-report diary entries
Study: 29912266
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of active asking and diaries
Study: 29912266
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of active asking and hotline
Study: 28407657
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids and vitamin E co-supplementation (1,000 mg omega-3 from flaxseed oil containing 400 mg α-Linolenic acid plus 400 IU vitamin E)
Study: 23748748
Drug: Ritonavir (0.1-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (0.1-300 mg)
Study: 19912513
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K (1 mg) on the day before surgery (group K)
Study: 19912513
Drug: Heparin bridging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bridging after the last VKA dose on day -5 before surgery (group H)
Study: 16856145
Drug: Rasagiline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (1 mg/2 mg); n = 38
Study: 16856145
Drug: Rasagiline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (0.5 mg/day); n = 22
Study: 16856145
Drug: Rasagiline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (1 mg/day); n = 12
Study: 10906651
Drug: Pulsed-dye laser
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed-dye laser (PDL) therapy (585 nm)
Study: 10906651
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (liquid nitrogen cryotherapy or cantharidin)
Study: 8854792
Drug: Continuous hyperthermic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperthermic pleural perfusion (CHPP) with 100 mg CDDP diluted in saline
Study: 8854792
Drug: Continuous hyperthermic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperthermic pleural perfusion (CHPP) with 100 mg CDDP diluted in distilled water
Study: 6443596
Drug: 1 ml/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/20 kg saline (Control)
Study: 30588947
Drug: Combined intrarectal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intrarectal lidocaine gel and periprostatic nerve block (cGPNB)
Study: 21884013
Drug: Ambrisentan 5
Normalized name: ambrisentan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 5 mg once daily for 24 weeks
Study: 20580035
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/d) for 20 weeks
Study: 20580035
Drug: Rosuvastatin/exercise (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin/exercise (10 mg/d + exercise training 3d/wk from week 10 to week 20)
Study: 20580035
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/d) and Rosuvastatin/exercise (10 mg/d + exercise training) combined
Study: 18007551
Drug: Metformin 500mg
Normalized name: METFORMIN 500MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500mg tid for 6 months
Study: 16121967
Drug: Clazosentan (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (0.2 mg/kg/hr)
Study: 16121967
Drug: Clazosentan (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (0.4 mg/kg/hr for 12 hours followed by 0.2 mg/kg/hr)
Study: 11835038
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 14 days
Study: 10999124
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (400 mg/day for six weeks) in Group I
Study: 1524655
Drug: Haloperidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5 mg/kg)
Study: 1524655
Drug: Reduced haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced haloperidol (0.5 mg/kg)
Study: 1524655
Drug: Haloperidol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10 mg) twice daily for 4 weeks
Study: 3886566
Drug: Diltiazem in
Normalized name: diltiazem Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem in combination with diuretics
Study: 3886566
Drug: Diltiazem in
Normalized name: diltiazem Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem in combination with other drugs
Study: 31295074
Drug: Biofilm-disrupting gel
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biofilm-disrupting gel (BlastX) plus debridement (standard of care)
Study: 31295074
Drug: Triple-antibiotic maximum-strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-antibiotic maximum-strength ointment (standard of care)
Study: 31295074
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to biofilm-disrupting gel after 4 weeks of standard care
Study: 25293665
Drug: Transcranial laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial laser therapy
Study: 20650346
Drug: Chitosan (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan (750 mg, 3 times per day) 30 minutes before meals
Study: 16842799
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg (CEE)
Study: 18365858
Drug: 17 beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg (E(2)/NETA)
Study: 11915588
Drug: Raloxifene HCl
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene HCl 60 mg
Study: 12095385
Drug: Abacavir, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir, 300 mg twice per day, while continuing all other antiretroviral therapy (n = 54)
Study: 12095385
Drug: Continuing all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuing all antiretroviral therapy (n = 57)
Study: 3169489
Drug: Pectin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin (15 g added to meal)
Study: 3169489
Drug: Methylcellulose (15
Normalized name: methylcellulose (15 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose (15 g added to meal, control)
Study: 30201324
Drug: 0.5 μg.kg−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg.kg−1 of dexmedetomidine (high Dex group)
Study: 30201324
Drug: 0.25 μg.kg−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 μg.kg−1 of dexmedetomidine (low Dex group)
Study: 23159100
Drug: Aggressive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive statin therapy
Study: 16817556
Drug: Graded dermal
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded dermal tuberculin test using 100%, 25%, 5%, and 1% tuberculin solution via prick test
Study: 12694144
Drug: Adrenaline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 0.5 micro g.ml‐1
Study: 12694144
Drug: Adrenaline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 1.0 micro g.ml‐1
Study: 12694144
Drug: Adrenaline 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 1.5 micro g.ml‐1
Study: 12694144
Drug: Adrenaline 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 2.0 micro g.ml‐1 (standard mixture)
Study: 3794300
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 40 micrograms HBsAg (months 0, 1, 6)
Study: 3794300
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 10 micrograms HBsAg (healthy controls)
Study: 3794300
Drug: 6 doses
Normalized name: interferon alfa-2b,recomb. 3 million unit/0.2 mL (6 doses per pen = 18 million unit) SUBCUT PEN INJECTOR KIT (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 doses of 40 micrograms HBsAg (monthly intervals)
Study: 3794300
Drug: 6 doses
Normalized name: interferon alfa-2b,recomb. 3 million unit/0.2 mL (6 doses per pen = 18 million unit) SUBCUT PEN INJECTOR KIT (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 doses of 20 micrograms HBsAg (monthly)
Study: 29500217
Drug: Metformin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (up to 2 g/day)
Study: 28112286
Drug: Training EMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training EMS personnel in recognizing and initiating treatment in the prehospital setting with early administration of antibiotics
Study: 22518369
Drug: Long-acting oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting oral morphine 30 mg orally twice daily for three days
Study: 16007008
Drug: 1% chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chitosan on 0.2% HCl in combination with methylene blue and IR laser beam (study group)
Study: 12605026
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cariporide
Study: 12605026
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg cariporide
Study: 12605026
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg cariporide
Study: 12605026
Drug: All cariporide
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All cariporide groups (20 mg, 80 mg, 120 mg)
Study: 10382587
Drug: HOMA-CIGMA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOMA-CIGMA with immunoreactive insulin
Study: 9147928
Drug: Intra-arterial cisplatinum
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial cisplatinum (CDP) with 3-drug protocol (MTX, CDP, ADM)
Study: 9147928
Drug: Intravenous cisplatinum
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatinum (CDP) with 3-drug protocol (MTX, CDP, ADM)
Study: 9147928
Drug: Intravenous cisplatinum
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatinum (CDP) with 4-drug protocol (MTX, CDP, ADM, IFO)
Study: 9147928
Drug: Intra-arterial cisplatinum
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial cisplatinum (CDP) with 4-drug protocol (MTX, CDP, ADM, IFO)
Study: 9147928
Drug: 4-drug protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug protocol (MTX, CDP, ADM, IFO)
Study: 26724101
Drug: Cannabidiol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol at 2-5 mg/kg per day, up-titrated to a maximum of 25 mg/kg or 50 mg/kg per day depending on study site.
Study: 21668681
Drug: Oseltamivir (Tamiflu(®);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (Tamiflu(®); Roche) 75 mg once daily prophylaxis
Study: 21668681
Drug: Seasonal influenza
Normalized name: seasonal influenza, intradermal, preservative free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal influenza vaccine (Fluviral(®))
Study: 18445082
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with a vaccine containing 50% of the wild grasses Trisetum paniceum and Dactylis glomerata, administered with a schedule of 0.1 and 0.2 mL at day 1, followed by 0.3 and 0.5 mL at day 7, 0.5 mL after 2 weeks, and 0.5 mL monthly, totaling a mean of 6.5 injections over 2.3 months.
Study: 16807413
Drug: Homocysteine-lowering treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homocysteine-lowering treatment (daily supplement containing folate 1000 microg, B12 500 microg, and B6 10 mg)
Study: 10740555
Drug: Regional diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional diamorphine 2.5 mg i.v.
Study: 9206054
Drug: Navoban (tropisetron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navoban (tropisetron, 5 mg)
Study: 9206054
Drug: Kytril (granisetron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kytril (granisetron, 3 mg)
Study: 1317641
Drug: 5 x
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 1 mg of gemeprost every 3 h
Study: 1317641
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 1 mg of gemeprost every 6 h
Study: 3975430
Drug: BW245C (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW245C (150 micrograms, 6-hourly for 5 days)
Study: 29431471
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein hypocaloric diet (2.0 g protein/kg/d)
Study: 29431471
Drug: Standard-protein hypocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-protein hypocaloric diet (1.0 g protein/kg/d)
Study: 19783371
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine infusion (0.35mg/kg/h, not to exceed 25mg/h over a 4h period) for 10 days
Study: 19783371
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (normal saline) for 10 days
Study: 12641538
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg) plus vitamin B6 (250 mg)
Study: 9174206
Drug: Amoxicillin 875
Normalized name: amoxicillin 875 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 875 mg orally
Study: 9174206
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g intramuscularly
Study: 4023620
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of secretin for 60 min
Study: 4023620
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of secretin and cholecystokinin for another 60 min
Study: 20174905
Drug: Valsartan (V)
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan (V) 160 mg once daily